Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 1/2016

01-01-2016 | Original Article – Clinical Oncology

Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain

Authors: Elena Laakmann, Kerstin Riecke, Yvonne Goy, Jan F. Kersten, Andreas Krüll, Volkmar Müller, Cordula Petersen, Isabell Witzel

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2016

Login to get access

Abstract

Purpose

Several prognostic indices (PI) have been developed to stratify patients with brain metastases in groups with good or bad prognosis. The aim of our study was to compare nine prognostic scores for patients with brain metastases (BM) of breast cancer receiving radiotherapy.

Methods

The clinical data of 139 breast cancer patients with BM were collected retrospectively. All patients were treated with cerebral radiotherapy or surgery followed by radiotherapy between January 2007 and December 2012. The prognostic value and accuracy of recursive partitioning analysis (RPA), RPA II, graded prognostic assessment (GPA), basic score for BM, Breast-RPA, Breast-GPA, Rades Score 2011, Germany Score and Breast Rades Score were assessed.

Results

The median survival after BM diagnosis in our cohort was 14 months. The overall 6-month, 1-, 2- and 3-year survival rates were 49.6, 37.4, 20.9 and 13.7 %, respectively. Most of the PI were associated with OS, but univariate analysis favored GPA regarding OS. GPA was the most accurate score to identify patients with long (longer than 12 months) and Breast-GPA patients with short (<3 months) life expectancy.

Conclusions

GPA and Breast-GPA seem to be the most useful scores and perform better than other PI for breast cancer patients with BM receiving radiotherapy.
Appendix
Available only for authorised users
Literature
go back to reference Antoni D, Clavier JB, Pop M, Schumacher C, Lefebvre F, Noel G (2013) Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors. Int J Radiat Oncol Biol Phys 86:630–637. doi:10.1016/j.ijrobp.2013.02.027 PubMedCrossRef Antoni D, Clavier JB, Pop M, Schumacher C, Lefebvre F, Noel G (2013) Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors. Int J Radiat Oncol Biol Phys 86:630–637. doi:10.​1016/​j.​ijrobp.​2013.​02.​027 PubMedCrossRef
go back to reference Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedCrossRef Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedCrossRef
go back to reference Müller V (2015) Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. J Clin Oncol 33:Abstract TPS 639 Müller V (2015) Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. J Clin Oncol 33:Abstract TPS 639
go back to reference Niikura N et al (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103–112. doi:10.1007/s10549-014-3090-8 PubMedCrossRef Niikura N et al (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103–112. doi:10.​1007/​s10549-014-3090-8 PubMedCrossRef
go back to reference Niwinska A, Tacikowska M, Pienkowski T (2007) Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol 46:1027–1029PubMedCrossRef Niwinska A, Tacikowska M, Pienkowski T (2007) Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol 46:1027–1029PubMedCrossRef
go back to reference Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514. doi:10.1016/j.ijrobp.2007.06.074 PubMedCrossRef Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514. doi:10.​1016/​j.​ijrobp.​2007.​06.​074 PubMedCrossRef
Metadata
Title
Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain
Authors
Elena Laakmann
Kerstin Riecke
Yvonne Goy
Jan F. Kersten
Andreas Krüll
Volkmar Müller
Cordula Petersen
Isabell Witzel
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-2049-4

Other articles of this Issue 1/2016

Journal of Cancer Research and Clinical Oncology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine